Nasolina (Oxymetazoline)

Oxymetazoline is a selective alpha‑adrenergic agonist. When applied to the nasal mucosa, it binds to alpha‑adrenergic receptors on the smooth muscle of blood vessels, causing vasoconstriction. This reduces blood flow and edema in the nasal lining, which quickly clears blockage and improves airflow.

The exact dosing regimen for Nasolina is determined by the prescribing healthcare professional or the product label. Typically, a few sprays per nostril are used no more than every 10‑12 hours, and use should not exceed three consecutive days to avoid rebound congestion.

Safety data for oxymetazoline in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using Nasolina to weigh potential benefits against any possible risks.

To place an order, submit an enquiry on the Nasolina product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasolina (oxymetazoline) provides rapid, localized vasoconstriction and is generally longer‑acting than phenylephrine sprays. Both belong to the same class of topical decongestants, but oxymetazoline often requires fewer daily applications. Choice depends on individual response, duration of therapy, and physician recommendation.

Nasolina should be stored at room temperature, away from direct sunlight and moisture. Keep the spray in its original container with the cap tightly closed. Do not expose it to extreme heat or freeze it, and discard any product that appears discolored or contaminated.

Nasolina is administered as a nasal spray. The user gently inserts the tip into one nostril, blocks the opposite nostril, and sprays the recommended number of sprays while inhaling gently. The same procedure is repeated for the other nostril if directed by the label or prescriber.

Serious adverse events, although rare, include rebound nasal congestion after prolonged use, significant elevation of blood pressure, rapid heart rate or arrhythmias, and severe nasal ulceration. If any of these occur, discontinue use immediately and seek medical attention.

Nasolina should not be used by children younger than six years, individuals with known hypersensitivity to oxymetazoline or any formulation ingredients, patients taking monoamine oxidase inhibitors, or anyone who has used other topical nasal decongestants within the past 24 hours without medical advice.